Physician profile
David A Travis
NPI 1184616393
$4,069.40
in general payments reported to CMS, 2019-2025
35 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $317 · 2021: $611 · 2022: $635 · 2023: $737 · 2024: $618 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $512.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $429.44 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $423.28 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $411.08 | 2019-2024 | Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.54 | 2019-2025 | Jardiance |
| Amgen INC. | $219.15 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $202.85 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $180.82 | 2019-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $164.71 | 2019-2023 | |
| Amarin Pharma, INC. | $140.75 | 2019-2022 | |
| Daiichi Sankyo INC. | $126.15 | 2019-2023 | Injectafer |
| Lexicon Pharmaceuticals, INC. | $110.53 | 2023-2024 | Inpefa |
| Philips North America LLC | $106.17 | 2021-2024 | (Ck4) Mcot |
| Novo Nordisk INC | $86.08 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Regeneron Healthcare Solutions, INC. | $65.53 | 2023-2024 | Evkeeza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $65.12 | 2019-2022 | |
| Atricure, INC. | $60.41 | 2020-2022 | |
| Edwards Lifesciences Corporation | $47.90 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inspire Medical Systems, INC. | $44.88 | 2024-2025 | Inspire |
| Abbott Laboratories | $39.98 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.33 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $31.99 | 2024 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $30.18 | 2020-2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $29.34 | 2022-2023 | Arcalyst |
| Lundbeck LLC | $27.95 | 2019-2020 | |
| Medtronic Vascular, INC. | $24.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.92 | 2019-2022 | |
| Lilly USA, LLC | $18.63 | 2025 | Zepbound |
| Esperion Therapeutics, INC. | $18.26 | 2021 | |
| Medtronic, INC. | $16.54 | 2021 | |
| Boston Scientific Corporation | $15.57 | 2023 | Bodyguardian |
| Biotronik INC. | $15.00 | 2019 | |
| Vifor Pharma, INC. | $13.64 | 2019 | |
| Lantheus Medical Imaging, INC. | $12.49 | 2019 | |
| Cashflow Solutions, LLC | $6.44 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Travis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.